Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for RBC Bioscience Corporation (6848:TWSE), powered by AI.
RBC Bioscience Corporation is currently trading at $20.50. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for RBC Bioscience Corporation on Alpha Lenz.
RBC Bioscience Corporation's P/E ratio is 13.6.
“RBC Bioscience Corporation trades at a P/E of 13.6 (undervalued) with solid ROE of 8.8%.”
Ask for details →RBC Bioscience Corporation is a biotechnology company specializing in the research, development, manufacturing, and sale of reagents and devices for life science and molecular diagnostics. Its primary function is to provide advanced tools for nucleic acid extraction and purification, including automated instruments equipped with ultraviolet sterilization systems and disposable reagent kits designed to enhance the efficiency and purity of DNA and RNA extraction. These products play a crucial role in clinical diagnostics, biomedical research, disease prevention, forensic testing, and genetic analysis, serving medical laboratories, research institutions, and healthcare providers across Europe, Asia, America, Africa, Australia, and Taiwan. Founded in 1995 and based in New Taipei City, Taiwan, RBC Bioscience is ISO9001 and CE certified, reflecting its commitment to high-quality manufacturing standards. The company's focus on innovation supports the molecular diagnostic sector by enabling reliable sample processing for applications such as disease tracking, treatment planning, and scientific discovery, making it a significant contributor to the global healthcare equipment and supplies market.
“RBC Bioscience Corporation trades at a P/E of 13.6 (undervalued) with solid ROE of 8.8%.”
Ask for details →RBC Bioscience Corporation (ticker: 6848) is a company listed on TWSE in the Healthcare sector (Biotechnology). It has approximately 52 employees. Market cap is $293M.
The current price is 20.5 with a P/E ratio of 13.57x and P/B of 1.17x.
ROE is 8.80% and operating margin is 17.44%. Annual revenue is $205M.